Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NQO1 | P15559 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.46 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.46 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29517404 | 1.00 | MAPT (0.58) | MAPTKDM4EHPGDNQO1ENPP2 | |
| SCHEMBL2202982 | 0.82 | ALDH1A1 (0.49) | MAPTKDM4EHPGDENPP2ORAI1 | |
| SCHEMBL7675242 | 0.82 | MAPT (0.42) | MAPTKDM4EHPGD | |
| SCHEMBL21223556 | 0.81 | MAPT (0.54) | MAPTKDM4EHPGDCYP1A2CYP2C9 | |
| SCHEMBL1642006 | 0.81 | ALOX5 (0.50) | MAPTKDM4EHPGD | |
| SCHEMBL29956903 | 0.81 | ALOX5 (0.50) | MAPTKDM4EHPGD | |
| SCHEMBL15330334 | 0.80 | KDM1A (0.42) | MAPTKDM4EHPGDMEN1KMT2A | |
| SCHEMBL28798247 | 0.80 | IDO1 (0.42) | MAPTKDM4EHPGDNQO1ENPP2 | |
| SCHEMBL2558327 | 0.79 | GAA (0.43) | MAPTCYP2C9 | |
| SCHEMBL25201352 | 0.79 | MEN1 (0.41) | MAPTKDM4EHPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117865773-A | Preparation method of difluoromethyl aromatic compound based on palladium-catalyzed decarbonylation coupling | 大连理工大学 | 2024-04-12 | — | — | CN | claimed |
| CN-109305981-B | Synthesis method of 2-hydroxynaphthalene-1-boric acid | 白银棓诺新材料有限公司 | 2021-10-29 | — | — | CN | claimed |
| US-6800784-B1 | REACTING AROMATIC COMPOUND CARRYING AT LEAST ONE AMINO GROUP AND LEAVING GROUP WITH ARYLBORONIC ACID OR DERIVATIVE THEREOF, IN AQUEOUS MEDIUM, AND IN PRESENCE OF EFFECTIVE QUANTITY OF PALLADIUM CATALYST | RHODIA CHIMIE (FR) | 2004-10-05 | — | — | US | claimed |
| US-6590100-B2 | Reacting an aromatic compound bearing a leaving group and an arylboronic acid and/or its derivatives in the presence of a base and an effective amount of a nickel catalyst | RHODIA CHIMIE (FR) | 2003-07-08 | — | — | US | claimed |
| US-20020173652-A1 | Process for preparing a polyaromatic compound | SHASUN PHARMA SOLUTIONS, INC. | 2002-11-21 | — | — | US | claimed |
| US-20260096277-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING SAME | LT MATERIALS CO., LTD. (KR) | 2026-04-02 | — | — | US | disclosed |
| US-12410180-B2 | Light-emitting device, light-emitting apparatus, electronic device, and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2025-09-09 | — | — | US | disclosed |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4548918-A2 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250115614-A1 | Organic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2025-04-10 | — | — | US | disclosed |
| CN-119661592-A | Monophosphine ligand oEPCP containing [2.2] p-cycloalkane skeleton structure, and preparation method and application thereof | 中国人民解放军海军军医大学 | 2025-03-21 | — | — | CN | disclosed |
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2025-02-25 | — | — | US | disclosed |
| US-20050065350-A1 | Method for forming a carbon-carbon or carbon-heteroatom linkage | SHASUN PHARMA SOLUTIONS, INC. | 2005-03-24 | — | — | US | disclosed |
| US-6800784-B1 | REACTING AROMATIC COMPOUND CARRYING AT LEAST ONE AMINO GROUP AND LEAVING GROUP WITH ARYLBORONIC ACID OR DERIVATIVE THEREOF, IN AQUEOUS MEDIUM, AND IN PRESENCE OF EFFECTIVE QUANTITY OF PALLADIUM CATALYST | RHODIA CHIMIE (FR) | 2004-10-05 | — | — | US | disclosed |
| US-20030236413-A1 | Catalysis in presence of a metallic element, an imine ligand and nitrogen compound as chelating compound, forming a chemical intermediates in the agrochemical and pharmaceutical fields | SHASUN PHARMA SOLUTIONS, INC. | 2003-12-25 | — | — | US | disclosed |
| US-20030171593-A1 | Process for arylating or vinylating or alkynating a nucleophilic compound | SHASUN PHARMA SOLUTIONS, INC. | 2003-09-11 | — | — | US | disclosed |
| US-6590100-B2 | Reacting an aromatic compound bearing a leaving group and an arylboronic acid and/or its derivatives in the presence of a base and an effective amount of a nickel catalyst | RHODIA CHIMIE (FR) | 2003-07-08 | — | — | US | disclosed |
| US-20020173652-A1 | Process for preparing a polyaromatic compound | SHASUN PHARMA SOLUTIONS, INC. | 2002-11-21 | — | — | US | disclosed |
| US-20020049316-A1 | Protease inhibitors | HALBERT STACIE MARIE (US) | 2002-04-25 | — | — | US | disclosed |
| WO-1995013284-A1 | ASYMMETRIC HYDROBORATION | ISIS INNOVATION LIMITED (GB) | 1995-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065350-A1 | Method for forming a carbon-carbon or carbon-heteroatom linkage | COX6C, CBR3, CBR1 | MAPT 3391/4885KDM4E 1884/4885HPGD 669/4885 |
| US-20250115614-A1 | Organic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device | NDUFC1, ARNT, NFE2L2 | MAPT 2498/4885KDM4E 3990/4885HPGD 1369/4885 |
| US-20030236413-A1 | Catalysis in presence of a metallic element, an imine ligand and nitrogen compound as chelating compound, forming a chemical intermediates in the agrochemical and pharmaceutical fields | ALK, INMT, ACHE | MAPT 3435/4885KDM4E 990/4885HPGD 2820/4885 |
| US-20020049316-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | MAPT 796/4885KDM4E 3001/4885HPGD 392/4885 |
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | MAPT 229/4885KDM4E 2534/4885HPGD 4385/4885 |
| US-20030171593-A1 | Process for arylating or vinylating or alkynating a nucleophilic compound | ALK, ALKBH3, NNMT | MAPT 3262/4885KDM4E 244/4885HPGD 2782/4885 |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | MAPT 4509/4885KDM4E 4221/4885HPGD 799/4885 |
| US-12410180-B2 | Light-emitting device, light-emitting apparatus, electronic device, and lighting device | SLC18A3, SLC1A2, SLC18A1 | MAPT 1843/4885KDM4E 3219/4885HPGD 2397/4885 |
| US-20260096277-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING SAME | CYP1A1, CYP1B1, CHRM1 | MAPT 3191/4885KDM4E 3459/4885HPGD 2434/4885 |
| US-20020173652-A1 | Process for preparing a polyaromatic compound | PAH, ALK, ITPA | MAPT 3747/4885KDM4E 2223/4885HPGD 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.